Blog

Nelson Advisors Partner Lloyd Price has been invited to lead the 'HealthTech M&amp;A and IPOs Panel' at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia. #GHE25 &nbsp;&nbsp; The Global Health Exhibition 2025 &nbsp;&nbsp; The Global Health Exhibition in Riyadh is a major event focused on healthcare innovation, investment, and transformation. It brings together global leaders from both the public and private sectors to discuss the future of healthcare. &nbsp;&nbsp; The exhibition features: &nbsp;&nbsp; Conferences: Including a Leaders Summit for high-level discussions, a Medical Excellence Forum, a Digital Health Forum, and a Venture Forum. Exhibition Floor: Showcasing the latest in healthcare technology, including digital health, AI, medical devices, and more. Networking: Opportunities for professionals, investors, and innovators to connect and explore partnerships. &nbsp;&nbsp; The event will take place from October 27-30, 2025, at the Riyadh Exhibition and Convention Center in Malham, Saudi Arabia.bringing together 1,000+ global presenters, 1,500+ exhibitors, and leading investors. &nbsp;&nbsp; The event capitalises on Saudi Arabia's dynamic healthcare market and its strategic position as a global investment hub. The event combines CME-accredited conferences, cutting-edge technology showcases, and exclusive investment forums, making it the definitive platform where healthcare innovation meets commercial opportunity in one of the world's most rapidly evolving markets. &nbsp;&nbsp; The Global Health Exhibition 2024The Global Health Exhibition in Saudi Arabia is a major annual event that has quickly grown to become a prominent platform for the healthcare industry, both regionally and globally. Here's a look at its history and development: &nbsp;&nbsp; Origins and Purpose &nbsp; The Global Health Exhibition was launched in 2018 under the patronage of the Saudi Ministry of Health. Its creation was a direct response to Saudi Arabia's ambitious Vision 2030 plan, which includes a significant focus on transforming and modernizing the country's healthcare sector. The exhibition was established to provide a business platform for local and international healthcare companies to connect with the Saudi market and contribute to the Kingdom's healthcare goals. &nbsp;&nbsp; The event is organized by Informa Life Sciences Exhibitions, which also manages other major healthcare events like Arab Health. &nbsp;&nbsp; Key Milestones and Growth &nbsp;&nbsp; First Edition (2018): The inaugural exhibition took place from September 10-12, 2018, at the Riyadh International Convention and Exhibition Center. It aimed to provide a platform for 10,000 attendees to engage with over 500 exhibiting companies. The event also featured a multi-disciplinary congress with a focus on topics like Healthcare Transformation, Investment, and Innovation.Rapid Expansion: The exhibition has seen remarkable growth in subsequent years, reflecting the significant investment and focus on healthcare in Saudi Arabia. The event has expanded in size, attendance, and the number of participating countries.Post-Pandemic Transformation: The 2023 and 2024 editions of the Global Health Exhibition marked a new, transformative phase. The event has become a key forum for global collaboration and has witnessed the signing of numerous agreements and partnerships in areas like pharmaceuticals, biotechnology, and digital health.2023 Edition: The 2023 exhibition, held from October 29-31, was themed "Invest in Health." It featured over 300 companies from 29 countries and focused on topics like preventive care, artificial intelligence, and biotechnology.2024 Edition: The 2024 edition, held from October 21-23, was also a major success. It reportedly drew over 105,000 visitors, with 72% of attendees being international. The event saw announced investments and deals exceeding SAR 50 billion (Saudi Riyals), including significant projects in pharmaceutical manufacturing and digital transformation. It was held at the Riyadh International Convention and Exhibition Center in Malham.The Future: The exhibition continues to grow. The 8th edition is scheduled for October 27-30, 2025, and is expected to be the largest yet, with a continued focus on "Invest in Health" and attracting a high level of international participation. &nbsp;&nbsp; Core Focus Areas &nbsp;&nbsp; The Global Health Exhibition is more than just a trade show; it's a comprehensive platform for industry development. Key focus areas have included: &nbsp;&nbsp; Vision 2030: The exhibition is a cornerstone of Saudi Arabia's Health Sector Transformation Program, showcasing progress and attracting investments to achieve the goals of Vision 2030.Investment and Partnerships: It serves as a crucial hub for attracting foreign investment and fostering partnerships between public and private sector entities, both local and international.Innovation and Technology: The event highlights cutting-edge medical technologies, including AI, digital health solutions, and biotechnology, that are transforming the healthcare landscape.Knowledge Exchange: Through its various forums and conferences (such as the Leaders' Summit, Medical Excellence Forum, and Digital Health Forum), the exhibition provides a platform for experts and policymakers to share knowledge and discuss best practices.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, or to schedule a meeting with Nelson Advisors at the Global Health Exhibition 2025 #GHE25 in Riyadh, Saudi Arabia, &nbsp;please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors to lead the 'HealthTech M&A and IPOs Panel' at the Global Health Exhibition 2025 #GHE25

AI powers big data analysis and automation workflows, showcasing neural networks and data streams for business. Artificial intelligence, machine learning, digital transformation and tech innovation.

Proprietary datasets have become a critical asset and a major source of competitive advantage in the healthtech industry. Unlike publicly available data, proprietary data is unique to a company, often collected through its own products, services, or partnerships. This exclusivity creates a powerful moat that is difficult for competitors to replicate.I. Value PropositionThe value proposition of proprietary data sets in healthtech is centered on their ability to create unique, high-quality, and actionable insights that improve health outcomes and reduce costs. This value is delivered to various stakeholders in the healthcare ecosystem:For Patients: Improved patient outcomes through personalized medicine, earlier disease diagnosis, and more effective treatment plans. Data from wearables, for example, can be used to provide real-time, continuous monitoring, and personalized health recommendations.For Healthcare Providers: Enhanced clinical decision-making through predictive analytics and AI-powered tools that identify at-risk patients, streamline workflows, and optimize resource allocation. Proprietary datasets can provide a more holistic view of a patient's health, including social determinants of health and lifestyle factors.For Payers and Insurers: The ability to reduce wasteful spending, predict and manage high-cost populations, and develop more effective value-based care models.For Life Sciences Companies (Pharma, Biotech): Accelerated drug discovery and development, faster clinical trial validation, and a deeper understanding of real-world evidence. This can lead to more targeted therapies and a higher success rate for new drugs.A strong value proposition is built on the unique benefits, cost savings, and differentiation a company's data offers compared to current practices. This is often backed by robust evidence and a clear demonstration of how the data addresses an unmet need.II. ValueThe value of proprietary healthtech data is multifaceted and can be quantified in several ways:Clinical Value: This is the most direct measure, showing how the data improves health outcomes. Examples include a diagnostic tool with a lower false positive rate, an algorithm that predicts disease progression, or a platform that improves medication adherence.Economic Value: This relates to cost savings and new revenue streams. The data can lead to reduced hospital readmissions, more efficient clinical trials, or the ability to offer premium pricing for a unique solution. Some estimates suggest that a single patient dataset can be worth hundreds or even thousands of dollars depending on its therapeutic focus and type.Operational Value: This includes improvements in efficiency, such as automating tasks, reducing administrative burdens, and optimizing hospital operations. Predictive analytics, for instance, can help healthcare organizations anticipate demand for services.Research Value: The data can be a valuable asset for research, driving new discoveries and fueling innovation in drug development and medical device creation. Companies can monetize this data through partnerships or by offering it to researchers. The value of a dataset is determined by several factors:Volume and Variety: A large and diverse dataset (e.g., combining claims, clinical, and social data) is more valuable for training powerful AI models.Uniqueness and Novelty: Data that is difficult for competitors to obtain, such as real-time streams from connected devices or rare genomic data, holds higher differentiation potential. Quality and Completeness: The data must be accurate, clean, and free from significant gaps.&nbsp; Context and Integration: Data that is well-contextualized and harmonized across different sources is more valuable for generating actionable insights.III. Strategic AdvantagesA proprietary data set is a powerful strategic asset that can create a sustainable competitive advantage, also known as a "data moat." This advantage is built on several key pillars:Defensible Competitive Moat: Unlike a patent, which eventually expires, a proprietary dataset can grow and become more valuable over time. As more data is collected, the company's algorithms and insights become more accurate, creating a self-reinforcing loop that is incredibly difficult for new entrants to replicate.Enhanced AI and Machine Learning Capabilities: Proprietary data is the essential fuel for developing and training superior AI models. Companies with unique datasets can build models that are more accurate, less biased, and better at addressing specific, high-value problems in healthcare. For example, a company that has trained a large language model (LLM) on thousands of healthcare entities and concepts can offer an AI assistant that is more accurate and less prone to "hallucinations" than a general-purpose model.Personalization and Customization: Unique data allows healthtech companies to build products and services that are highly personalized to individual patients, providers, or organizations. This leads to better engagement, improved outcomes, and stronger customer loyalty.New Product and Service Development: The insights derived from proprietary data can be the basis for entirely new product lines or business models. For instance, a company analyzing real-world evidence from its data could identify new therapeutic applications for an existing drug or pinpoint a previously unknown disease pattern.Increased Valuation and Attractiveness for M&amp;A: Companies with valuable, proprietary datasets are often more attractive to investors and potential acquirers. The data itself is a key asset that can be leveraged for future growth and innovation.In summary, proprietary datasets are not just a tool for healthtech companies; they are the foundation for building a defensible market position, creating outsized value for all stakeholders, and driving the future of healthcare innovation.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Proprietary Datasets in HealthTech: Value Proposition and Strategic Advantages

Doctors and the Virtual Medical Revolution and Technological Advances Artificial Intelligence (AI) Deep Learning for Medical Research and Future Health Technology

Contrarian positioning in healthtech is the strategy of deliberately taking a position that goes against the current popular narrative or trend. In the current market, this often means emphasising a solution that doesn't rely on artificial intelligence (AI) when most companies are rushing to brand themselves as "AI-powered."This approach is powerful because it can help a company stand out in a crowded market and address a specific, unmet need. Instead of being one of many AI-first solutions, a company with a "non-AI story" can focus on a unique value proposition that may be more appealing to certain customers or investors.The Power of a 'Non-AI Story' in HealthTechA 'non-AI story' can be a highly effective marketing and business strategy in the healthtech sector for several key reasons:&gt; Differentiation: The market is saturated with healthtech startups claiming to use AI. A company that deliberately avoids this narrative can immediately differentiate itself. This can make the company's message more memorable and compelling. For example, instead of "An AI-driven platform for patient engagement," a company might say, "A human-centric platform that streamlines doctor-patient communication."&gt; Building Trust: Many healthcare professionals and patients are wary of AI due to concerns about data privacy, algorithmic bias, and the potential for errors. A non-AI story can build trust by emphasizing human expertise, manual oversight, and a more traditional, verifiable approach. This can be particularly appealing in highly regulated or sensitive areas of healthcare where trust is paramount.&gt; Solving Practical Problems: Not every problem in healthcare requires an AI solution. Many issues can be solved more effectively and affordably with well-designed software, improved workflows, or better human-to-human communication tools. A non-AI story allows a company to focus on solving a tangible, practical problem without the complexity and cost associated with developing and deploying AI models.&gt; Appealing to a Niche Market: There's a segment of the market that may be more comfortable with a non-AI approach. This could include smaller clinics, rural hospitals, or older healthcare professionals who are less technologically inclined or simply prefer a more straightforward solution. By taking a contrarian position, a company can target this specific group and become a leader in that niche.&gt; Highlighting Unique Strengths: A non-AI story forces a company to highlight other competitive advantages, such as superior user experience, seamless integration with existing systems, or exceptional customer support. These are often the true differentiators that get lost in the hype of AI.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Contrarian positioning and the power of a 'Non AI story' in HealthTech

Nelson Advisors is a highly specialised advisory firm with a singular focus on the healthcare technology sector. It is precisely defined as a mergers and acquisitions, partnerships and investment advisory firm that operates within the dynamic and rapidly evolving HealthTech landscape. This exclusive dedication to a specific industry is the bedrock of the firm's value proposition, providing a nuanced understanding of the unique market dynamics and technological advancements that are essential for successful transactions in this complex field. &nbsp; The firm's primary physical presence is in London, UK, positioning it strategically within the European HealthTech hub. While its physical headquarters are in Europe, its geographic scope is deliberately broad, catering to a client base that spans the UK, Europe, and North America. The international capabilities of its partners are extensive, with corporate finance experience and transaction exposure across numerous countries, including the US, Ireland, Sweden, Denmark, Switzerland, Germany, Austria, Italy, Poland, Ukraine, Russia, Kazakhstan, Hong Kong, Singapore, and Australia. This international reach allows the firm to facilitate complex, cross-border transactions that are increasingly common in the global HealthTech market. &nbsp;&nbsp; Exclusive Specialisation in the HealthTech Ecosystem &nbsp;&nbsp; The core of Nelson Advisors' business model is its deep and exclusive specialisation in the HealthTech sector. This focus is a significant competitive advantage over generalist firms, enabling the firm to develop a sophisticated understanding of the industry's complex dynamics. The firm’s expertise extends across a diverse range of sub-sectors, which demonstrates a comprehensive grasp of the entire HealthTech ecosystem. &nbsp;&nbsp; The firm’s specialised sub-segments include: &nbsp;&nbsp; Digital Health: This area covers a broad range of technology-driven solutions, including mobile health apps, telehealth platforms, wearable devices, and personalized wellness solutions.HealthTech: The firm’s focus here is on fundamental technological innovations in healthcare, such as advanced medical devices, robotics, bioprinting, and nanotechnology. These are often associated with early-stage companies and startups developing novel solutions to healthcare challenges.Health IT: This specialisation centres on the technology used to manage, store, and share health information, including systems like electronic health records (EHRs) and clinical decision support tools.Consumer Health: The firm advises companies that provide solutions directly to the end user, including AI-driven diagnostics and digital biomarkers.Healthcare Cybersecurity: This is a crucial area of specialisation dedicated to ensuring the confidentiality, integrity, and availability of sensitive healthcare information and systems. The firm's focus on this segment is a direct response to the sensitive nature of patient data and the increasing sophistication of cyber threats.Healthcare AI: This sub-sector leverages AI techniques like machine learning and natural language processing to analyse complex medical data, provide insights, and enhance operational efficiency. &nbsp;&nbsp; The firm's explicit inclusion of Healthcare AI and Cybersecurity is not just a listing of services but a strategic signal of long-term foresight. The partners understand that these specific, complex, and high-growth areas will be central to future value creation and risk management in HealthTech. The firm's proactive specialisation in these sub-sectors, which are subject to emerging regulations like the EU AI Act and the European Health Data Space (EHDS), distinguishes them from firms with a more general HealthTech focus. This expertise is invaluable for clients who need to navigate advanced technological landscapes and stringent regulatory environments.To discuss how Nelson Advisors can help your Healthtech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors: Boutique European HealthTech Investment Banking Firm

Dollar money shape in lights in downtown district office business buildings at night

As of mid-2025, the high valuation multiples for healthcare AI in Europe are being driven by a powerful confluence of macroeconomic, technological, and regulatory factors. This is creating a "perfect storm" that is making AI-native companies particularly attractive to investors and strategic buyers.Here are the key drivers:1. Strategic Imperative for Efficiency and OutcomesAging Population and Workforce Shortages: Europe's demographic trends are putting immense pressure on its healthcare systems. AI is seen as a critical tool to address this by automating administrative tasks, improving clinician productivity, and freeing up staff to focus on patient care. Investors are paying a premium for solutions that can deliver tangible savings and alleviate burnout. Shift to Value-Based Care: The European healthcare ecosystem is increasingly moving away from a fee-for-service model towards one that rewards positive patient outcomes and cost-effectiveness. AI is a key enabler of this shift through tools like predictive analytics, remote monitoring, and personalized treatment plans. Companies that can demonstrate a clear and measurable ROI in this context are highly valued. Massive Data Growth: Healthcare data is expanding at an exponential rate. AI is the only technology capable of making sense of this data to improve diagnostics, streamline clinical trials, and inform drug discovery. Companies that have proprietary, high-quality datasets and the AI to leverage them are seen as having a strong, defensible moats.2. Maturing Regulatory Environment and Investor ConfidenceClarity from the EU AI Act: The implementation of the EU AI Act, which will be fully applicable in the coming years, is providing much-needed regulatory clarity. This reduces risk for both developers and investors, as it establishes a framework for the ethical and safe use of AI in healthcare. This confidence translates into higher multiples. Supportive EU Policies: Broader initiatives like the European Health Data Space (EHDS) are designed to facilitate the secure exchange of health data across the EU. This is a game-changer for AI development, as it provides a foundation for training and deploying more robust AI models, thereby attracting more investment.Renewed Investor Interest: After a period of caution, capital is flowing back into the European digital health sector. Private equity firms and venture capital funds, sitting on significant "dry powder," are actively seeking out AI companies as a key component of their investment strategies. This increased competition for high-quality assets is directly pushing up valuations.3. Technological and Business Model SophisticationProven Clinical Validation: The market is moving beyond early-stage experimentation. Investors are demanding that companies demonstrate real-world, clinical validation of their AI solutions. Firms that have proven their effectiveness through pilot programs, clinical studies, or partnerships are commanding a premium.Integration and "Workflow Lock-in": AI solutions that are deeply integrated into existing clinical workflows (e.g., EHRs, imaging systems) are highly valued. This "sticky" nature of the product creates high switching costs for customers and ensures sustained revenue, which is a major driver of valuation multiples.Focus on Niche, High-Impact Areas: Investment is becoming more selective and is concentrated in areas where AI can have a significant and immediate impact. This includes diagnostics (e.g., medical imaging analysis), drug discovery, and physician support tools. This selective demand for specialized solutions drives up the multiples for leaders in these sub-sectors.Strategic "String-of-Pearls" M&amp;A: Large biopharma and medtech companies are using M&amp;A to acquire AI capabilities and fill pipeline gaps. They are not just buying technology; they are buying a competitive advantage. This strategic interest from cash-rich buyers is a powerful force behind the elevated valuations.To discuss how Nelson Advisors can help your MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a> &nbsp;

What is driving the healthcare AI valuation multiples in Europe mid 2025?

Hands Holding Virtual Healthcare Symbols Including, Family Insurance, Medical Report, Heartbeat, Medication, Ambulance Representing Health Services, Insurance Coverage, Digital Healthcare Solutions

Based on current market trends, Nelson Advisors team experience and industry publications to date in 2025, here are 10 key variables driving HealthTech M&amp;A valuations in Europe in 2025:1) AI Integration and Innovation: Companies with proven and proprietary AI algorithms, especially those in diagnostics, drug discovery, and predictive analytics, are commanding premium valuations. Buyers are actively acquiring these technologies to gain a competitive edge and improve operational efficiency. AI is a dominant force, with firms lagging in its adoption facing a valuation discount. 2) Shift to Value-Based Care: As healthcare systems in Europe move away from a fee-for-service model, companies that enable this transition are becoming more attractive. This includes firms with technologies for remote patient monitoring, population health management, and other solutions that deliver measurable cost savings and improved patient outcomes. Acquiring companies that can demonstrate a clear return on investment in a value-based care environment is a key driver. 3) Strong Financial Metrics and Growth Profile: While many healthtech companies are not yet profitable, buyers are scrutinizing financial health. Higher multiples are awarded to companies with a strong, sustainable revenue growth trajectory, high gross margins, and a significant percentage of recurring revenue.4) Intellectual Property (IP) Portfolio: A robust and defensible IP portfolio, including patents and proprietary technology, provides a significant competitive advantage. Companies with strong IP are viewed as less risky and are highly sought after, leading to higher valuations. This is particularly crucial in the highly competitive European market. 5) Favourable Economic and Regulatory Environment: The current economic and regulatory landscape is fueling deal activity. Abundant "dry powder" from private equity firms, along with a more business-friendly regulatory stance and a clearer framework for digital health tools (like the EU's AI Act), are giving buyers more confidence to invest. 6) Strategic Consolidation: Larger healthcare players are using M&amp;A to consolidate their market presence, achieve economies of scale, and fill strategic gaps. This "string of pearls" strategy involves acquiring smaller, innovative companies to enhance core platforms, expand geographic reach, and strengthen product pipelines against upcoming patent cliffs. 7) Data Monetisation and Interoperability: The ability to ethically and efficiently leverage patient data is a key value driver. Companies with clean, actionable data and solutions that enable seamless interoperability with Electronic Health Records (EHRs) and other systems are commanding higher multiples. 8) Niche Specialisations and High-Growth Sub-sectors: Valuations can vary widely by sub-sector. Companies operating in high-growth, specialized areas such as robotics, advanced surgical solutions, and specific therapeutic areas like ophthalmology, oncology, and rare diseases are seeing strong interest and higher valuations. 9) Stage of Company Development: The maturity and stage of a company's development significantly impacts its valuation. More mature companies with established commercial traction and deeper product pipelines are highly sought after by buyers looking for less risk and a quicker return on investment. 10) Alternative Deal Structures: There's a growing preference for alternative deal structures, including earn-outs, royalties, licensing agreements, and joint ventures. These structures are used to share risk and finance innovation, especially in the biotech and diagnostics sectors where regulatory and reimbursement risks are high. This flexibility helps bridge valuation gaps between buyers and sellers.To discuss how Nelson Advisors can help your HealthTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Nelson Advisors to lead the 'HealthTech M&A and IPOs Pane...

Proprietary Datasets in HealthTech: Value Proposition and...

Contrarian positioning and the power of a 'Non AI story' ...

Nelson Advisors: Boutique European HealthTech Investment ...

What is driving the healthcare AI valuation multiples in ...

10 key variables driving HealthTech M&A valuations in Eur...